Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Vidal

Showing results (311-320 of 339) with videos related to

Pageof 34
Sort By:
Aging Cell|March 27, 2025
IGF2-Reprogrammed Macrophages Ameliorate the Inflammatory Response and Protect Against the Neuroinflammatory Process in Parkinson's Disease ModelsFelipe Grunenwald, Tomas J Huerta, Denisse Sepulveda, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 31, 2019
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumabC Panciroli, G Lucente, L Vidal, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 8, 2021
Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation StudyBeau Toskich, Lucas L Vidal, Matthew T Olson, et al.
ESMO Open|May 8, 2024
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and driversL Vidal, Z Dlamini, S Qian, et al.
Angewandte Chemie (International Ed. in English)|July 24, 2024
Towards a Sustainable Future: Challenges and Opportunities for Early-Career ChemistsEmiel Dobbelaar, Shaimaa S Goher, Juliana L Vidal, et al.
NPJ Parkinson'S Disease|July 13, 2023
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's diseaseAmica C Müller-Nedebock, Marieke C J Dekker, Matthew J Farrer, et al.
Journal of Neurochemistry|August 5, 2025
Doxorubicin Induces a Senescent Phenotype in Murine and Human AstrocytesMariana Marques, Lívia de Sá Hayashide, Pedro Amorim, et al.
Journal of Clinical Medicine|July 12, 2025
Clinical Predictors of Inpatient Mortality and Poor Postoperative Course After aSAH Microsurgical Clipping: A 10-Year Experience from a Peruvian Tertiary Care CenterFernando Terry, Alejandro Enríquez-Marulanda, Nathaly Chinchihualpa-Paredes, et al.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
Cell Death Discovery|December 2, 2023
IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson's disease modelsJaviera Arcos, Felipe Grunenwald, Denisse Sepulveda, et al.
Pageof 34

Showing results (311-320 of 339) with videos related to

Sort By:
Pageof 34
Aging Cell|March 27, 2025
IGF2-Reprogrammed Macrophages Ameliorate the Inflammatory Response and Protect Against the Neuroinflammatory Process in Parkinson's Disease ModelsFelipe Grunenwald, Tomas J Huerta, Denisse Sepulveda, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 31, 2019
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumabC Panciroli, G Lucente, L Vidal, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 8, 2021
Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation StudyBeau Toskich, Lucas L Vidal, Matthew T Olson, et al.
ESMO Open|May 8, 2024
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and driversL Vidal, Z Dlamini, S Qian, et al.
Angewandte Chemie (International Ed. in English)|July 24, 2024
Towards a Sustainable Future: Challenges and Opportunities for Early-Career ChemistsEmiel Dobbelaar, Shaimaa S Goher, Juliana L Vidal, et al.
NPJ Parkinson'S Disease|July 13, 2023
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's diseaseAmica C Müller-Nedebock, Marieke C J Dekker, Matthew J Farrer, et al.
Journal of Neurochemistry|August 5, 2025
Doxorubicin Induces a Senescent Phenotype in Murine and Human AstrocytesMariana Marques, Lívia de Sá Hayashide, Pedro Amorim, et al.
Journal of Clinical Medicine|July 12, 2025
Clinical Predictors of Inpatient Mortality and Poor Postoperative Course After aSAH Microsurgical Clipping: A 10-Year Experience from a Peruvian Tertiary Care CenterFernando Terry, Alejandro Enríquez-Marulanda, Nathaly Chinchihualpa-Paredes, et al.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
Cell Death Discovery|December 2, 2023
IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson's disease modelsJaviera Arcos, Felipe Grunenwald, Denisse Sepulveda, et al.
Pageof 34